ArticleJournal of managed care & specialty pharmacy2022

The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with

Steve Duff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.